共 50 条
- [21] Interim results from a phase I/II study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN)ANNALS OF ONCOLOGY, 2023, 34 : S486 - S486Choudhury, N.Jain, P.Dowlati, A.Thompson, J.Johnson, M. L.Mamdani, H.Sanborn, R. E.Schenk, E. L.Aggarwal, R.Sankar, K.Walker, L. N.Anand, B.Beltran, H.
- [22] Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Johnson, Melissa LynneDy, Grace K.Mamdani, HirvaDowlati, AfshinSchoenfeld, Adam JacobPacheco, Jose MariaSanborn, Rachel E.Menon, Smitha PatiyilSantiago, LindaYaron, YifahBeltran, Himisha
- [23] Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY TrialJOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) : 104 - 110Damaj, GandhiGressin, RemyBouabdallah, KrimoCartron, GuillaumeChoufi, BachraGyan, EmmanuelBanos, AnneJaccard, ArnaudPark, SophieTournilhac, OlivierSchiano-de Collela, Jean-MarcVoillat, LaurentJoly, BertrandLe Gouill, StevenSaad, AlainCony-Makhoul, PascaleVilque, Jean-PierreSanhes, LaurenceSchmidt-Tanguy, AlineBubenheim, MichaelHouot, RochDiouf, MomarMarolleau, Jean-PierreBene, Marie-ChristineMartin, AntoineLamy, Thierry
- [24] A phase II, open-label, combination therapy of durvalumab and ceralasertib in relapsed and refractory small cell lung cancer (SUKSES-N4).JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Lee, Se-HoonKim, JiyeonPark, SehhoonMortimer, Peter G.Kim, HeejungSmith, SimonDean, EmmaKim, Yu JungJung, Hyun AeSun, Jong-MuPark, Woong-YangAhn, Jin SeokAhn, Myung-JuPark, Keunchil
- [25] Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3+tumors: Focus on Asian ptsANNALS OF ONCOLOGY, 2023, 34 : S1495 - S1495Kuboki, Y.Gambardella, V.Capdevila Castillon, J.Alese, O. B.Morgensztern, D.Sayehli, C. M.Sanmamed, M. F.Arriola, E.Wolf, J.Owonikoko, T. K.Studeny, M.Bouzaggou, M.Song, E.Wermke, M.
- [26] Phase I Dose Escalation Trial Of The DLL3/CD3 Igg-Like T Cell Engager BI 764532 In Patients with DLL3+Tumors: Focus on SCLCJOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S45 - S46Wermke, M.Kuboki, Y.Felip, E.Alese, O. B.Morgensztern, D.Sayehli, C.Arriola, E.Sanmamed, M. F.Oum'Hamed, Z.Song, E.Studeny, M.Gambardella, V.
- [27] Open-Label Phase 2 Study Of The Bispecific T-Cell Engager (BiTE®) Blinatumomab In Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaBLOOD, 2013, 122 (21)Viardot, AndreasGoebeler, MarielePfreundschuh, MichaelAdrian, NicoleLibicher, MartinDegenhard, EvelynStieglmaier, JuliaZhang, AliciaNagorsen, DirkBargou, Ralf C.
- [28] First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC)JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Wermke, MartinFelip, EnriquetaKuboki, YasutoshiMorgensztern, DanielSayehli, CyrusSanmamed, Miguel F.Arriola, EdurneOum'Hamed, ZohraSong, EricStudeny, MatusGambardella, Valentina
- [29] Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed/refractory small cell lung cancer (SCLC).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Byers, Lauren AverettChiappori, AlbertoSmit, Marie-Anne Damiette
- [30] Phase II Trial of metronomic Temozolomide and Topotecan in patients with relapsed and/or refractory Small Cell Lung Cancer.JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S743 - S743Bhattacharyya, Gouri ShankarParikh, Purvish M.Biswas, GhanashyamBondarde, Shailesh A.Malhotra, HemantVora, AmishGovindbabu, K.Ranade, Anantbhushan A. B.